Literature DB >> 30637861

Diffusion kurtosis imaging-derived histogram metrics for prediction of KRAS mutation in rectal adenocarcinoma: Preliminary findings.

Yanfen Cui1, Xue'e Cui2, Xiaotang Yang1, Zhizheng Zhuo3, Xiaosong Du1, Lei Xin1, Zhao Yang1, Xintao Cheng1.   

Abstract

BACKGROUND: Although histological examination is the standard method for assessing genetic status, the development of a noninvasive method, which can display the heterogeneity of the whole tumor to supplement genotype analysis, might be important for personalized treatment strategies.
PURPOSE: To evaluate the potential role of diffusion kurtosis imaging (DKI)-derived parameters using histogram analysis derived from whole-tumor volumes for prediction of the status of KRAS mutations in patients with rectal adenocarcinoma. STUDY TYPE: Retrospective.
SUBJECTS: In all, 148 consecutive patients with histologically confirmed rectal adenocarcinoma who were treated at our institution. SEQUENCE: DKI was performed with a 3.0 T MRI system using a single-shot echo-planar imaging sequence with b values of 0, 700, 1400, and 2100 sec/mm2 . ASSESSMENT: D, K, and apparent diffusion coefficient (ADC) values were measured using whole-tumor volume histogram analysis and were compared between different KRAS mutations status. STATISTICAL TESTS: Student's t-test or Mann-Whitney U-test, and receiver operating characteristic (ROC) curves were used for statistical analysis.
RESULTS: All the percentile metrics of ADC and D values were significantly lower in the mutated group than those in the wildtype group (all P < 0.05), except for the minimum value of ADC and D (both P > 0.05), while K-related percentile metrics were higher in the mutated group compared with those in the wildtype group (all P < 0.05). Regarding the comparison of the diagnostic performance of all the histogram metrics, K75th showed the highest AUC value of 0.871, and the corresponding values for sensitivity, specificity, positive predictive value, and negative predictive value were 81.43%, 78.21%, 77.03%, and 82.43%, respectively. DATA
CONCLUSION: DKI metrics with whole-tumor volume histogram analysis is associated with KRAS mutations, and thus may be useful for predicting the KRAS status of rectal cancers for guiding targeted therapy. LEVEL OF EVIDENCE: 3 Technical Efficacy: Stage 2 J. Magn. Reson. Imaging 2019;50:930-939.
© 2019 International Society for Magnetic Resonance in Medicine.

Entities:  

Keywords:  diffusion kurtosis imaging; histogram; mutations; rectal cancer

Year:  2019        PMID: 30637861     DOI: 10.1002/jmri.26653

Source DB:  PubMed          Journal:  J Magn Reson Imaging        ISSN: 1053-1807            Impact factor:   4.813


  4 in total

1.  Pretreatment Apparent Diffusion Coefficient Cannot Predict Histopathological Features and Response to Neoadjuvant Radiochemotherapy in Rectal Cancer: A Meta-Analysis.

Authors:  Alexey Surov; Maciej Pech; Maciej Powerski; Katja Woidacki; Andreas Wienke
Journal:  Dig Dis       Date:  2021-03-04       Impact factor: 2.404

2.  T2*-weighted imaging and diffusion kurtosis imaging (DKI) of rectal cancer: correlation with clinical histopathologic prognostic factors.

Authors:  Shan Hu; Yang Peng; Qiushi Wang; Bin Liu; Ihab Kamel; Zaiyi Liu; Changhong Liang
Journal:  Abdom Radiol (NY)       Date:  2021-12-27

3.  Magnetic Resonance-Based Texture Analysis Differentiating KRAS Mutation Status in Rectal Cancer.

Authors:  Ji Eun Oh; Min Ju Kim; Joohyung Lee; Bo Yun Hur; Bun Kim; Dae Yong Kim; Ji Yeon Baek; Hee Jin Chang; Sung Chan Park; Jae Hwan Oh; Sun Ah Cho; Dae Kyung Sohn
Journal:  Cancer Res Treat       Date:  2019-05-07       Impact factor: 4.679

4.  Update of the recommendations for the determination of biomarkers in colorectal carcinoma: National Consensus of the Spanish Society of Medical Oncology and the Spanish Society of Pathology.

Authors:  P García-Alfonso; R García-Carbonero; J García-Foncillas; P Pérez-Segura; R Salazar; R Vera; S Ramón Y Cajal; J Hernández-Losa; S Landolfi; E Musulén; M Cuatrecasas; S Navarro
Journal:  Clin Transl Oncol       Date:  2020-05-16       Impact factor: 3.405

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.